‘Being there’ for women with metastatic breast cancer: a pan-European patient survey

• Published in: British journal of cancer 2013-09, Vol.109 (6), p.1543-1548
• Main Authors: Harding, V, Afshar, M, Krell, J, Ramaswami, R, Twelves, C J, Stebbing, J
• Format: Article
• Language: English
• Subjects: 692/699/67/1347; 692/699/67/322; 692/700; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Breast Neoplasms - psychology; Cancer Research; Clinical Study; Data Collection; Drug Resistance; Epidemiology; Europe; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Middle Aged; Molecular Medicine; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Needs Assessment; Neoplasm Metastasis; Oncology; Patient Satisfaction; Surveys and Questionnaires; Tumors; Young Adult
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2013.492

Background: Understanding their experiences of diagnosis is integral to improving the quality of care for women living with advanced/metastatic breast cancer. Methods: A survey, initiated in March 2011, was conducted in two stages. First, the views of 47 breast cancer-related patient groups in eight European countries were sought on standards of breast cancer care and unmet needs of patients. Findings were used to develop a patient-centric survey to capture personal experiences of advanced breast cancer to determine insights into the ‘trade-off’ between extending overall survival and side effects associated with its treatment. The second online survey was open to women with locally advanced or metastatic breast cancer, or their carers, and responders were recruited through local patient groups. Data were collected via anonymous local language questionnaires. Results: The online stage II survey received a total of 230 responses from 17 European countries: 94% of respondents had locally advanced or metastatic breast cancer and 6% were adult carers. Although the overall experience of care was generally good/excellent (77%), gaps were still perceived in terms of treatment choice and information provision. Treatment choice for patients was felt to be lacking by 32% of responders. In addition, 68% of those who responded would have liked more information about future medical treatments and research, with 57% wishing to receive this information from their oncologist. Two-thirds (66%) of women with advanced breast cancer, or their carers, believed life-extending treatment to be important so that they can spend more time with family and friends, and 67% said that the treatment was worthwhile, despite potential associated side effects. Conclusion: These findings show a continuing need to provide women with advanced breast cancer with better information and emphasise the importance that these patients often place on prolonging survival.